HCV Archives – Page 5 of 31 – Treatment Action Group

Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci

August 23, 2022
Dorrit Walsh

Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.

Treatment Action Group Adds Three New Board Members

August 23, 2022
Dorrit Walsh

As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available

August 1, 2022
Dorrit Walsh

Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.

LAT CAB Video Presentation

July 28, 2022
Dorrit Walsh

This video, offered here in English, French, and Spanish, was made to be shown at the AfroCAB booth at the 24th International AIDS Conference.

Cover of Pipeline Report 2022. Black cover with grey type and decorative bright green lines

2022 Pipeline Report

July 24, 2022
Dorrit Walsh

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

Research in Action Awards 2022

July 8, 2022
Dorrit Walsh

Save the date for Tuesday, November 16, 2021! TAG’s 2021 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world. This year we’ll once again gather virtually to ensure this year’s event is safe and open for participation to our allies and friends across the U.S. and world.

Treatment Action Group Statement on NYC DOHMH Monkeypox Vaccination Announcement

June 23, 2022
Dorrit Walsh

In response to this morning's announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group's Executive Director, Mark Harrington, and TAG HIV Project Director Riko A. Boone, MSW, MPH, MA, said:

Cover of TAG's annual report. Reads: 2021 TAG Annual Report, Progress in the Fight for better treatment, prevention, a vaccine, and a cure for HIV, Tuberculosis, and Hepatitis C Virus

2021 Annual Report

June 3, 2022
Dorrit Walsh

This year we celebrate the unending dedication and accomplishments of TAG’s staff. They persevered through the challenges of an ongoing pandemic in 2021 to find new ways to carry out our work.

Treatment Action Group Mourns Urvashi Vaid, Celebrates Her Life and Legacy

May 17, 2022
Dorrit Walsh

Treatment Action Group (TAG) today mourns the premature loss of transformative LGBTQ and AIDS activist Urvashi Vaid, formerly executive director of the National Gay and Lesbian Task Force (now the National LGBTQ Task Force) at the height of the U.S. AIDS crisis in the late 1980s and early 1990s, and peerless leader of the LBGTQ movement for many years thereafter.

Joint Statement from Leading HIV/AIDS and Viral Hepatitis Advocates regarding Manufacturer Action on the 340B Drug Pricing Program

April 20, 2022
Dorrit Walsh

A group of six leading HIV/AIDS and viral hepatitis advocates today released the following joint statement regarding recent manufacturer action against the 340B Drug Pricing Program: